Current research trends of nanomedicines
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Owing to the inherent shortcomings of traditional therapeutic drugs in terms of inadequate therapeutic efficacy and toxicity in clinical treatment, nanomedicine designs have received widespread attention with significantly improved efficacy and reduced non-target side effects. Nanomedicines hold tremendous theranostic potential for treating, monitoring, diagnosing, and controlling various diseases and are attracting an unfathomable amount of input of research resources. Against the backdrop of an exponentially growing number of publications, it is imperative to help the audience get a panorama image of the research activities in the field of nanomedicines. Herein, this review elaborates on the development trends of nanomedicines, emerging nanocarriers, in vivo fate and safety of nanomedicines, and their extensive applications. Moreover, the potential challenges and the obstacles hindering the clinical translation of nanomedicines are also discussed. The elaboration on various aspects of the research trends of nanomedicines may help enlighten the readers and set the route for future endeavors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“The tumor vascular system is distinguished from normal blood vessels by complicated, heterogeneous leaky vessels with heterogeneous blood flow 211,212 , which can promote passive tumor targeting and accumulation of nanocarriers based on the EPR effect 213,214 .”
BackgroundBiomolecular coronas provide the biological identity of nanosized materials
Monopoli, M. P., Åberg, C., Salvati, A., & Dawson, K. A. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.207 · Cited by 3,017
Maeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376 · cited 1×
“The tumor vascular system is distinguished from normal blood vessels by complicated, heterogeneous leaky vessels with heterogeneous blood flow 211,212 , which can promote passive tumor targeting and accumulation of nanocarriers based on the EPR effect 213,214 .”
BackgroundRapid formation of plasma protein corona critically affects nanoparticle pathophysiology
Tenzer, S., Docter, D., Kuharev, J., Musyanovych, A., Fetz, V., Hecht, R., Schlenk, F., Fischer, D., Kiouptsi, K., Reinhardt, C., et al. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2013.181 · Cited by 2,283
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222 · cited 2×
“This could have a meaningful impact on how nanocarriers are used to diagnose and treat tumor development and metastasis 219 .”
BackgroundProgress and challenges towards targeted delivery of cancer therapeutics
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-03705-y · Cited by 2,220
Nanoparticle Size and Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake
Walkey, C. D., Olsen, J. B., Guo, H., Emili, A., & Chan, W. C. W. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2084338 · Cited by 1,926 · cited 1×
“Additionally, more plasma proteins are drawn to charged or hydrophobic interfaces 246 e 248 .”
BackgroundAggarwal, P., Hall, J. B., McLeland, C. B., Dobrovolskaia, M. A., & McNeil, S. E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.009 · Cited by 1,791
Nanoparticles in the clinic: an update
Anselmo, A. C., & Mitragotri, S. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10143 · Cited by 1,766
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Sharifi, S., Behzadi, S., Laurent, S., Laird Forrest, M., Stroeve, P., & Mahmoudi, M. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15188f · Cited by 1,460
The current landscape of nucleic acid therapeutics
Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., & van der Meel, R. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00898-0 · Cited by 1,371 · cited 1×
“However, many challenges remain due to degradation by nucleases 344 , dif-ficulty in encapsulation 345 , poor membrane penetration 346 , and off-target effects 347 .”
BackgroundDiverse Applications of Nanomedicine
Pelaz, B., Alexiou, C., Alvarez-Puebla, R. A., Alves, F., Andrews, A. M., Ashraf, S., Balogh, L. P., Ballerini, L., Bestetti, A., Brendel, C., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b06040 · Cited by 1,350
Schöttler, S., Becker, G., Winzen, S., Steinbach, T., Mohr, K., Landfester, K., Mailänder, V., & Wurm, F. R. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2015.330 · Cited by 1,272 · cited 1×
“The prevalence of clusters in PC was shown to limit macrophage absorption of non-specific cells 275 .”
BackgroundBioMOFs: Metal–Organic Frameworks for Biological and Medical Applications
McKinlay, A. C., Morris, R. E., Horcajada, P., Férey, G., Gref, R., Couvreur, P., & Serre, C. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201000048 · Cited by 1,256 · cited 1×
“MOF has flexible variable and adjustable properties and thus can be used as nano-carriers to load various types of drugs 112 .”
BackgroundApolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C., & Alyautdin, R. (2002) · Journal of drug targeting · doi:10.1080/10611860290031877 · Cited by 801 · cited 2×
“The plasma protein ApoE can bind preferentially to nanoparticles coated with polysorbate 80, promoting nanoparticle accumulation in the brain 199 .”
BackgroundFang, J., Islam, W., & Maeda, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.005 · Cited by 757 · cited 1×
“Increasing nano-medicines are utilized for targeted cancer therapy via the EPR effect 336 .”
BackgroundTherapeutically harnessing extracellular vesicles
Cheng, L., & Hill, A. F. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00410-w · Cited by 737 · cited 1×
“However, even though extensive studies have demonstrated the promise of EVs-based drug delivery systems, clinical translation of EVs-based therapeutics remains challenging, owing to obstacles such as low drug loading, low isolation yield, potential safety concerns, and considerable complexity 90 .”
BackgroundHwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699 · cited 1×
“…and constituents such as liposomes 46,47 , nanocrystals, 48 e 52 carrier-free nanoassemblies, 53 albumin nanoparticles 54 , polymeric micelles 55 , and nanoemulsions 56 have been intensively investigated both in basic research and commercial translation 57 Liposomes (Doxil (cid:2) , 1995)…”
BackgroundPreparation and application of pH-responsive drug delivery systems
Ding, H., Tan, P., Fu, S., Tian, X., Zhang, H., Ma, X., Gu, Z., & Luo, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.056 · Cited by 645 · cited 1×
“The pH-responsive approach can be used for precise delivery, using the pH gradients between normal and diseased tissues 162 .”
Optical nano-agents in the second near-infrared window for biomedical applications
Cai, Y., Wei, Z., Song, C., Tang, C., Han, W., & Dong, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00494c · Cited by 603 · cited 1×
“…chemical bonds 130 ; 2) induce responsive drug release at target sites 131 ; 3) activate temperature changes in photothermal therapy (PTT) 132 ; 4) generate reactive oxygen species (ROS) in photodynamic therapy (PDT) 133 ; 5) mediate light-activated imaging for multi-mode theranostics 134 .”
BackgroundComplement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo
Chen, F., Wang, G., Griffin, J. I., Brenneman, B., Banda, N. K., Holers, V. M., Backos, D. S., Wu, L., Moghimi, S. M., & Simberg, D. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2016.269 · Cited by 599 · cited 2×
“Complement proteins can attach to nanomedicines’ PC and be exchanged in vivo when nanomedicines are introduced into the blood 265 .”
BackgroundNagai, H., Okazaki, Y., Chew, S. H., Misawa, N., Yamashita, Y., Akatsuka, S., Ishihara, T., Yamashita, K., Yoshikawa, Y., Yasui, H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110013108 · Cited by 535
Inorganic nanomaterials with rapid clearance for biomedical applications
Wang, X., Zhong, X., Li, J., Liu, Z., & Cheng, L. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00461h · Cited by 509
The dawn of mRNA vaccines: the COVID-19 case
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.043 · Cited by 504
Treuel, L., Brandholt, S., Maffre, P., Wiegele, S., Shang, L., & Nienhaus, G. U. (2014) · ACS Nano · doi:10.1021/nn405019v · Cited by 419
Cloaking nanoparticles with protein corona shield for targeted drug delivery.
Oh, J. Y., Kim, H. S., Palanikumar, L., Go, E. M., Jana, B., Park, S. A., Kim, H. Y., Kim, K., Seo, J. K., Kwak, S. K., et al. (2018) · Nature communications · doi:10.1038/s41467-018-06979-4 · Cited by 409
Modulating Pharmacokinetics, Tumor Uptake and Biodistribution by Engineered Nanoparticles
Arvizo, R. R., Miranda, O. R., Moyano, D. F., Walden, C. A., Giri, K., Bhattacharya, R., Robertson, J. D., Rotello, V. M., Reid, J. M., & Mukherjee, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024374 · Cited by 403
COVID-19 vaccines: The status and perspectives in delivery points of view
Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375 · cited 1×
“For instance, to meet the urgent need in 2020, two types of lipid-based messenger RNA (mRNA) vaccines (Pfizer BioNTech Vaccine and Moderna COVID-19 Vaccine) were launched because they could effectively deliver antigens, mimic the structure of the coronavirus, and serve as adjuvant ideally 28,29 .”
BackgroundBrain-targeted drug delivery by manipulating protein corona functions
Zhang, Z., Guan, J., Jiang, Z., Yang, Y., Liu, J., Hua, W., Mao, Y., Li, C., Lu, W., Qian, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11593-z · Cited by 334 · cited 1×
“Bionic liposomes with a peptide tag are associated with exchangeable apolipoproteins and absorb significant amounts of ApoA1, E, and J, improving the bionic liposomes’ ability to target the brain 278 .”
BackgroundUltrasound-responsive systems as components for smart materials
Athanassiadis, A. G., Ma, Z., Moreno-Gomez, N., Melde, K., Choi, E., Goyal, R., & Fischer, P. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00622 · Cited by 293
Approaches to surface engineering of extracellular vesicles
Richter, M., Vader, P., & Fuhrmann, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.020 · Cited by 258 · cited 1×
“In addition, various functionalized modifications have been engineered on EVs to reinforce their natural features 87 .”
Schleich, N., Po, C., Jacobs, D., Ucakar, B., Gallez, B., Danhier, F., & Préat, V. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.059 · Cited by 238
Xue, X., Zhao, Y., Dai, L., Zhang, X., Hao, X., Zhang, C., Huo, S., Liu, J., Liu, C., Kumar, A., et al. (2014) · Advanced Materials · doi:10.1002/adma.201302365 · Cited by 206
Anionic Lipid Nanoparticles Preferentially Deliver mRNA to the Hepatic Reticuloendothelial System
Pattipeiluhu, R., Arias‐Alpizar, G., Basha, G., Chan, K. Y. T., Bussmann, J., Sharp, T. H., Moradi, M., Sommerdijk, N., Harris, E. N., Cullis, P. R., et al. (2022) · Advanced Materials · doi:10.1002/adma.202201095 · Cited by 194 · cited 1×
“…potential to selectively target hepatic reticuloendothelial system (RES) via the comprehensive in vivo biodistribution and clearance mechanismofLNPs 76 Also,LNPscantargetthespleenandlungsby replacing standard helper lipids with anionic (phosphatidylserine, phosphatidylglycerol, and phosphatidic…”
BackgroundCell membrane-derived vesicles for delivery of therapeutic agents
Le, Q.-V., Lee, J., Lee, H., Shim, G., & Oh, Y.-K. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.01.020 · Cited by 181 · cited 1×
“They inherit the plasticity and flexibility of synthetic materials and the diverse biological functionalities of biomimetic materials 99 .”
BackgroundXiao, W., Wang, Y., Zhang, H., Liu, Y., Xie, R., He, X., Zhou, Y., Liang, L., & Gao, H. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120888 · Cited by 174 · cited 5×
“For instance, EVs show the potential to cross the blood ‒ brain barrier (BBB) and blood ‒ brain tumor barrier (BBTB), one of the most intriguing and challenging obstacles in brain delivery.”
BackgroundInfluentialTheranostic USPIO‐Loaded Microbubbles for Mediating and Monitoring Blood‐Brain Barrier Permeation
Lammers, T., Koczera, P., Fokong, S., Gremse, F., Ehling, J., Vogt, M., Pich, A., Storm, G., van Zandvoort, M., & Kiessling, F. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201401199 · Cited by 156
The in vivo fate of polymeric micelles
Cai, Y., Qi, J., Lu, Y., He, H., & Wu, W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114463 · Cited by 154
Self-citationEnhanced immunocompatibility of ligand-targeted liposomes by attenuating natural IgM absorption
Guan, J., Shen, Q., Zhang, Z., Jiang, Z., Yang, Y., Lou, M., Qian, J., Lu, W., & Zhan, C. (2018) · Nature Communications · doi:10.1038/s41467-018-05384-1 · Cited by 152 · cited 1×
“Adhesion of IgM to liposome surfaces, whether naked or surface-modified, negatively impacts complement activation 263,286,287 .”
BackgroundNakamura, T., Sato, Y., Yamada, Y., Abd Elwakil, M. M., Kimura, S., Younis, M. A., & Harashima, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114417 · Cited by 121 · cited 1×
“…interests and redeveloped to tackle unmet needs in the delivery of more challengeable entities, notably mRNA and deoxyribonucleic acid (DNA) antigens 66 , oligonucleotides 67 , and CRISPR 68 LNPs integrate the advantages of conventional colloidal nanocarriers while negating some related drawbacks.”
BackgroundDelivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles
Evers, M. J. W., Du, W., Yang, Q., Kooijmans, S. A. A., Vink, A., van Steenbergen, M., Vader, P., de Jager, S. C. A., Fuchs, S. A., Mastrobattista, E., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.027 · Cited by 113
Yokoi, K., Kojic, M., Milosevic, M., Tanei, T., Ferrari, M., & Ziemys, A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3494 · Cited by 95 · cited 1×
“This is correlated with the ratio of tissue inhibitor of metalloproteinase one to matrix metalloproteinase 9 (MMP-9), indicating that elevated MMP-9 levels are indicative of higher vascular permeability 217,218 .”
BackgroundWu, D., Shi, X., Zhao, F., Chilengue, S. T. F., Deng, L., Dong, A., Kong, D., Wang, W., & Zhang, J. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.06.033 · Cited by 81
Unmasking CSF protein corona: Effect on targeting capacity of nanoparticles
Wang, Y., Zhang, H., Xiao, W., Liu, Y., Zhou, Y., He, X., Xia, X., Gong, T., Wang, L., & Gao, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.04.001 · Cited by 48
Cited by
Uti, D. E., Egbung, J. E., Anthony, B. O., Omari, O. R., Omang, W. A., Aggad, W. S., Almohaimeed, H. M., Bainsal, N., Shukla, S. K., Ealla, K. K. R., et al. (2026) · Discover Nano · doi:10.1186/s11671-026-04681-9 · Cited by 3
Metadata
- Authors
- Liu, Q., Zou, J., Chen, Z., He, W., & Wu, W.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2023-11
- Volume
- 13
- Issue
- 11
- Pages
- 4391-4416
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W4377157472
- Cited by
- 213
- References
- 45
- FWCI
- 11.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.